Bayer 1Q Earnings Hurt by Glyphosate Business, Inflation
By Cecilia Butini
Bayer on Thursday posted a fall first-quarter earnings, which the company said were weighed by an impairment loss due to reduced market price expectations on the herbicide glyphosate, and inflation.
The German pharmaceutical and agricultural company posted net profit of 2.18 billion euros ($2.39 billion), down from EUR3.29 billion the previous year and short of analysts' forecasts of EUR2.21 billion. Earnings before interest, taxes, depreciation and amortization before special items declined to EUR4.47 billion from EUR5.25 billion the year prior while earnings before interest and taxes fell to EUR2.97 billion from EUR4.21 billion in the same quarter of 2022, Bayer said.
Sales declined to EUR14.39 billion from EUR14.64 billion, missing a consensus forecast that saw them at EUR14.59 billion.
The company said its agricultural business, Crop Science, saw herbicide sales declining by more than 24% due to lower volumes and prices for glyphosate-based products, though other parts of the business grew.
The Pharmaceuticals division also had a decline in prescription-drug sales, due to tender procedures and a Covid-19 wave in China, Bayer said.
The company nonetheless backed its 2023 guidance, saying that it expects to reach the lower end of the target range. Chief Executive Werner Baumann said, however, that he sees potential risks coming from reduced market price expectations for glyphosate-based products in the remainder of the year.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
May 11, 2023 02:15 ET (06:15 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
After Earnings, Is Coinbase Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Albemarle Stock a Buy, a Sell, or Fairly Valued?
-
Is ServiceNow Stock a Buy After Earnings and Its Investor Day?
-
3 Stocks to Buy and 3 Stocks to Sell After Earnings
-
Markets Brief: Is It Really a Surprising Quarter for Earnings?
-
After Earnings, Is Berkshire Hathaway Stock a Buy, a Sell, or Fairly Valued?
-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
Today’s Market Volatility Could Provide Tomorrow’s Opportunities
-
40 of the Best Investment Picks
-
Tech Stock Dividends Are Changing the Face of Dividend Growth Investing
-
Roblox Earnings: Weakening Engagement Has Weighed On Growth
-
The Best Gaming Stocks to Buy
-
Energy Transfer Earnings: M&A Drives Guidance Increase In Solid Quarter
-
The Best Healthcare Stocks to Buy
-
Going Into Earnings, Is Home Depot Stock a Buy, a Sell, or Fairly Valued?